Related Experiment Video
Updated: Aug 18, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
A comparison of two commercial recombinant vaccines for hepatitis B in adolescents
G Leroux-Roels1, B Abraham, M Fourneau
1Centre for Vaccinology, University of Ghent-University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Abstract:
The immunogenicity and reactogenicity profiles of three doses each of Engerix-B(R) (10 microg hepatitis B surface antigen) and Recombivax(R) (5 microg hepatitis B surface antigen), given on a 0, 1, 6 month schedule to healthy adolescents were compared in a single-blind, randomized clinical trial. One month following the third dose, seroprotection rates after Engerix-B and Recombivax were similar (99 and 98%, respectively). The geometric mean titre (GMT) was statistically significantly higher following vaccination with Engerix-B (3961 vs. 1001 mIU/ml; P=0.0001, Fisher's exact test). Most of the symptoms reported were mild or moderate in intensity and transient. There were no vaccine-related serious adverse events.
Related Concept Videos
Bioequivalence studies: Biowaivers
Hepatitis
Viral Hepatitis I: Introduction

